EHA 2014 | Impressive results from phase 3 RESONATE trial in CLL

Peter Hillmen

Prof Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the results of the phase 3 RESONATE trial of 391 patients with relapsed or refractory chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL). Prof Hillmen outlines the progression-free and overall survival results which showed the significant benefits of ibrutinib over ofatumumab. He comments on single versus combination therapy with ibrutinib in CLL.

Share this video